RxDoctor Payments Data

James Shepard, MD

Internal Medicine · Philadelphia, PANPI 1447284856

Payments from drug & device makers

$1,808in general payments, 2019–2025

Across 110 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$421
  • Merck$325
  • Viiv Healthcare Company$257
  • Janssen Products, LP$196
  • GSK$163
  • Boehringer Ingelheim$120
  • plus $324 from 9 others

What the payments were for

  • Speaking & faculty fees$151%
  • Food & beverage$1,53785%
  • Education$25514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,808 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$28,973
Medicare patients
102
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala63$238,570
GenvoyaElviteg/Cob/Emtri/Tenof Alafen49$197,696
DovatoDolutegravir Sodium/Lamivudine35$102,745
EliquisApixaban84$77,953
JanuviaSitagliptin Phosphate70$67,072
JardianceEmpagliflozin47$52,720
PrezcobixDarunavir/Cobicistat22$52,092
TivicayDolutegravir Sodium16$46,170
TriumeqAbacavir/Dolutegravir/Lamivudi12$44,071
OzempicSemaglutide31$31,584
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$30,398
Dimethyl Fumarate13$27,273
XareltoRivaroxaban21$27,256
VraylarCariprazine Hcl11$20,891
Breo ElliptaFluticasone/Vilanterol41$16,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$50$436,266112 claims
Viiv Healthcare CompanyDovato, Tivicay, Triumeq$257$192,98663 claims
Johnson & JohnsonPrezcobix, Xarelto$48$79,34843 claims
MerckJanuvia$325$67,07270 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$163$58,630109 claims
Boehringer IngelheimJardiance$120$52,72047 claims
AbbVieVraylar$421$20,89111 claims
AstraZenecaSymbicort$88$3,98618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →